576 related articles for article (PubMed ID: 37444586)
1. Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy.
Zheng Z; Li S; Liu M; Chen C; Zhang L; Zhou D
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444586
[TBL] [Abstract][Full Text] [Related]
2. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
[TBL] [Abstract][Full Text] [Related]
3. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
4. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.
Xu C; Ju D; Zhang X
Antib Ther; 2022 Jan; 5(1):73-83. PubMed ID: 35372786
[TBL] [Abstract][Full Text] [Related]
7. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.
Chen Q; Lu L; Ma W
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497465
[TBL] [Abstract][Full Text] [Related]
9. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
10. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
13. Strategies for manufacturing cell therapy products aligned with patient needs.
Guha P; Katz SC
Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
15. CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy.
Cui Y; Luo M; Gu C; He Y; Yao Y; Li P
Biophys Rep; 2023 Oct; 9(5):279-297. PubMed ID: 38516299
[TBL] [Abstract][Full Text] [Related]
16. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.
Chen T; Wang M; Chen Y; Liu Y
Cancer Cell Int; 2024 Apr; 24(1):133. PubMed ID: 38622705
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma.
Esmaeilzadeh A; Tahmasebi S; Athari SS
Biomed Pharmacother; 2020 Mar; 123():109685. PubMed ID: 31862474
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
19. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Bozorgi A; Bozorgi M; Khazaei M
Cell Oncol (Dordr); 2022 Oct; 45(5):755-777. PubMed ID: 35943716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]